Monday, January 18, 1999
When GelTex Pharmaceuticals Inc. began its Cholestagel program five
years ago, the company said that to be economically and clinically attractive, the
non-absorbed cholesterol-binding polymer would have to reduce cholesterol by 18-20 percent
at a dose of 2 grams.
The company last week released positive Phase III data that, while
statistically significant, don't hit those old dose reduction numbers. Nevertheless, GELX
believes it has an approvable, economically attractive and commercially competitive drug
that will allow it to gain a foothold in the cholesterol lowering market while it readies
an improved second-generation product.